NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $3.64 -0.19 (-4.97%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.47▼$3.9250-Day Range$2.55▼$4.1152-Week Range$0.36▼$6.04Volume432,473 shsAverage Volume769,802 shsMarket Capitalization$300.89 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ADC Therapeutics alerts: Email Address ADC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside147.6% Upside$9.00 Price TargetShort InterestBearish3.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.12 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.92) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.13 out of 5 starsMedical Sector615th out of 936 stocksPharmaceutical Preparations Industry284th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageADC Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.85% of the outstanding shares of ADC Therapeutics have been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in ADC Therapeutics has recently increased by 289.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 2.2 News and Social Media Coverage News SentimentADC Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for ADCT on MarketBeat in the last 30 days. MarketBeat Follows5 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have bought 632.68% more of their company's stock than they have sold. Specifically, they have bought $1,124,000.00 in company stock and sold $153,410.00 in company stock.Percentage Held by InsidersOnly 4.05% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($1.92) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About ADC Therapeutics Stock (NYSE:ADCT)ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More ADCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Stock News HeadlinesJuly 4, 2024 | insidertrades.comRedmile Group, Llc Buys 400,000 Shares of ADC Therapeutics SA (NYSE:ADCT) StockJuly 19, 2024 | americanbankingnews.comADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 11, 2024 | investorplace.com7 Growth Stocks to Buy for Under $5 for Massive GainsJuly 8, 2024 | globenewswire.comMyricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentJune 27, 2024 | globenewswire.comADC Therapeutics Set to Join Russell 2000® and Russell 3000® IndexesJune 13, 2024 | investorplace.comStocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a BudgetJune 3, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…May 30, 2024 | globenewswire.comADC Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 15, 2024 | globenewswire.comADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finance.yahoo.comADC Therapeutics First Quarter 2024 Earnings: In Line With ExpectationsMay 9, 2024 | finance.yahoo.comInsider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)May 9, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | globenewswire.comADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth OutlookMay 7, 2024 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call TranscriptMay 6, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsSee More Headlines Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees310Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+147.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-240,050,000.00 Net Margins-330.17% Pretax Margin-267.68% Return on EquityN/A Return on Assets-55.36% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio4.35 Sales & Book Value Annual Sales$68.62 million Price / Sales4.39 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book-1.88Miscellaneous Outstanding Shares82,777,000Free Float79,425,000Market Cap$300.89 million OptionableOptionable Beta1.59 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ameet Mallik M.B.A. (Age 51)M.S., CEO & Director Comp: $1.84MMr. Jose I. Carmona M.B.A. (Age 52)Chief Financial Officer Comp: $884.86kDr. Mohamed Zaki M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $2.41MMs. Lisa Michelle KalleboCorporate Controller & Chief Accounting OfficerDr. Michael Mulkerrin Ph.D. (Age 69)Chief Technical Operations Officer Dr. Patrick van Berkel Ph.D. (Age 56)Chief Scientific Officer Amanda HamiltonInvestor Relations OfficerMr. Peter J. Graham Esq. (Age 57)Chief Legal Officer Ms. Eugenia LitzVice President of Investor Relations & Corporate CommunicationsMs. Kimberly Pope (Age 57)Senior VP & Chief People Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRMersana TherapeuticsNASDAQ:MRSNC4 TherapeuticsNASDAQ:CCCCCytomX TherapeuticsNASDAQ:CTMXiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 205,221 shares on 7/26/2024Ownership: 0.248%Sanibel Captiva Trust Company Inc.Bought 10,000 shares on 7/22/2024Ownership: 0.137%Redmile Group, LlcBought 400,000 shares on 7/1/2024Total: $1.12 M ($2.81/share)Robert AzelbySold 6,995 sharesTotal: $20,215.55 ($2.89/share)Sanibel Captiva Trust Company Inc.Bought 103,000 shares on 5/21/2024Ownership: 0.124%View All Insider TransactionsView All Institutional Transactions ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $1.66 at the beginning of 2024. Since then, ADCT shares have increased by 119.0% and is now trading at $3.6350. View the best growth stocks for 2024 here. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings results on Monday, May, 6th. The company reported ($0.56) earnings per share for the quarter, hitting the consensus estimate of ($0.56). The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $18.19 million. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $126 million in an IPO on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.25%), Sanibel Captiva Trust Company Inc. (0.14%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby. View institutional ownership trends. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA). This page (NYSE:ADCT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADCT with Qtrade Free ADCT Stock Alerts